Bioceres Crop Solutions (NASDAQ:BIOX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.11), Zacks reports. The business had revenue of $39.40 million for the quarter, compared to the consensus estimate of $54.50 million. Bioceres Crop Solutions had a negative net margin of 92.85% and a negative return on equity of 29.01%.
Bioceres Crop Solutions Price Performance
NASDAQ BIOX traded down $0.03 during trading hours on Wednesday, reaching $0.42. 211,930 shares of the stock traded hands, compared to its average volume of 751,223. The stock has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $1.02. Bioceres Crop Solutions has a 1 year low of $0.35 and a 1 year high of $5.18. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.90 and a quick ratio of 0.69. The company has a market cap of $26.49 million, a price-to-earnings ratio of -0.11 and a beta of 0.39.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Wall Street Zen lowered Bioceres Crop Solutions from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Weiss Ratings lowered Bioceres Crop Solutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.00.
Institutional Investors Weigh In On Bioceres Crop Solutions
A number of large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its holdings in shares of Bioceres Crop Solutions by 3,535.8% in the first quarter. Jones Financial Companies Lllp now owns 5,490 shares of the company’s stock worth $25,000 after buying an additional 5,339 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Bioceres Crop Solutions by 318.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 107,641 shares of the company’s stock worth $141,000 after buying an additional 81,924 shares during the period. Jane Street Group LLC purchased a new position in shares of Bioceres Crop Solutions in the second quarter worth about $202,000. Squarepoint Ops LLC purchased a new position in shares of Bioceres Crop Solutions in the third quarter worth about $233,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Bioceres Crop Solutions in the third quarter worth about $315,000. Hedge funds and other institutional investors own 17.68% of the company’s stock.
About Bioceres Crop Solutions
Bioceres Crop Solutions Corp. is an agricultural biotechnology company focused on developing, manufacturing and commercializing a range of crop inputs designed to enhance yields and improve sustainability. The company’s portfolio includes biological seed treatments, inoculants for nitrogen fixation, specialty fertilizers and proprietary biopesticides, which are formulated to support plant health and resilience under varying environmental conditions.
Among its flagship offerings is the HB4 drought-tolerant wheat technology, the first genetically modified wheat developed to withstand water stress, which has received regulatory approval in several markets.
Featured Stories
- Five stocks we like better than Bioceres Crop Solutions
- Qualcomm Stock Doubles: New Era? Or Another False Start?
- 3 Industrial Stocks That Just Crushed Earnings
- A Quantum Shift: Why Speculative Money Is Ditching AI
- Reading the Stripes: Is The Industrial Recession Over?
Receive News & Ratings for Bioceres Crop Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioceres Crop Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
